All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ticagrelor 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
platelet aggregation inhibitors	4184	274693-27-5

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: ticagrelor brilinta AZD 6140 possia brilique

a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP-receptor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction Molecular weight: 522.57 Formula: C23H28F2N6O4S CLOGP: 3.35 LIPINSKI: 1 HAC: 10 HDO: 4 TPSA: 138.44 ALOGS: -3.92 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.18	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	1.25 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.38 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.80 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
July 20, 2011	FDA	ASTRAZENECA LP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vascular stent thrombosis	686.68	18.07	126	12901	851	63475144
Rhabdomyolysis	588.48	18.07	249	12778	43702	63432293
Myocardial infarction	343.43	18.07	228	12799	99665	63376330
Thrombosis in device	286.28	18.07	75	12952	2915	63473080
Drug interaction	281.44	18.07	287	12740	228844	63247151
Dyspnoea	269.35	18.07	482	12545	660831	62815164
Acute myocardial infarction	261.82	18.07	129	12898	31995	63444000
Gastrointestinal haemorrhage	179.58	18.07	142	12885	81034	63394961
Acute kidney injury	171.67	18.07	239	12788	263176	63212819
Haemorrhage	129.01	18.07	104	12923	60918	63415077
Haemorrhage intracranial	118.59	18.07	57	12970	13362	63462633
Acute coronary syndrome	108.03	18.07	49	12978	10077	63465918
Vascular stent stenosis	104.64	18.07	24	13003	529	63475466
Hypersensitivity myocarditis	102.30	18.07	20	13007	196	63475799
Angina pectoris	101.49	18.07	68	12959	30010	63445985
Cerebral haemorrhage	100.17	18.07	68	12959	30661	63445334
Chest pain	96.80	18.07	165	12862	215794	63260201
Coronary artery stenosis	95.00	18.07	36	12991	4708	63471287
Angina unstable	87.47	18.07	38	12989	7057	63468938
Melaena	82.24	18.07	60	12967	30305	63445690
Epistaxis	79.75	18.07	86	12941	72639	63403356
Asphyxia	79.13	18.07	34	12993	6147	63469848
Chest discomfort	70.19	18.07	99	12928	109870	63366125
Cardiogenic shock	68.93	18.07	44	12983	17888	63458107
Coronary artery occlusion	61.07	18.07	31	12996	8160	63467835
Bradycardia	60.75	18.07	75	12952	73152	63402843
Coronary artery disease	59.67	18.07	51	12976	32326	63443669
Anaemia	58.96	18.07	162	12865	293268	63182727
Myopathy	57.29	18.07	33	12994	11158	63464837
Sinus arrest	54.77	18.07	19	13008	1930	63474065
Eosinophilia	50.63	18.07	40	12987	22716	63453279
Cardiac arrest	49.92	18.07	77	12950	92468	63383527
Atrioventricular block complete	49.49	18.07	27	13000	8224	63467771
Labelled drug-drug interaction medication error	49.32	18.07	32	12995	13367	63462628
Haematoma	48.74	18.07	47	12980	34773	63441222
Cardiac failure	47.84	18.07	74	12953	89068	63386927
Upper gastrointestinal haemorrhage	43.81	18.07	34	12993	18818	63457177
Coronary artery thrombosis	43.54	18.07	14	13013	1125	63474870
Coronary artery restenosis	43.41	18.07	11	13016	373	63475622
Platelet function test abnormal	40.24	18.07	8	13019	86	63475909
Arthralgia	39.95	18.07	35	12992	569675	62906320
Ventricular asystole	38.85	18.07	8	13019	104	63475891
Myositis	38.77	18.07	24	13003	9242	63466753
Electrocardiogram ST segment elevation	38.73	18.07	18	13009	3909	63472086
Drug ineffective	37.86	18.07	101	12926	1044664	62431331
Diabetic macroangiopathy	37.48	18.07	8	13019	125	63475870
Atrioventricular block	35.06	18.07	21	13006	7626	63468369
Intentional product misuse	34.69	18.07	52	12975	60865	63415130
Coronary artery dissection	34.61	18.07	11	13016	851	63475144
Arthropathy	34.30	18.07	4	13023	234788	63241207
Brain natriuretic peptide increased	33.90	18.07	18	13009	5195	63470800
Faeces discoloured	33.78	18.07	29	12998	18480	63457515
Acid base balance abnormal	31.87	18.07	8	13019	261	63475734
Infusion related reaction	31.69	18.07	6	13021	245515	63230480
Myocardial ischaemia	31.64	18.07	24	13003	12835	63463160
Subarachnoid haemorrhage	31.54	18.07	25	13002	14258	63461737
Cholestasis	30.82	18.07	34	12993	29400	63446595
Cerebral haematoma	30.59	18.07	15	13012	3668	63472327
Arterial restenosis	30.29	18.07	5	13022	16	63475979
Restenosis	29.97	18.07	4	13023	0	63475995
Alveolar proteinosis	29.45	18.07	8	13019	357	63475638
Pyrexia	29.36	18.07	32	12995	470446	63005549
Product name confusion	29.28	18.07	6	13021	76	63475919
Hepatitis acute	29.27	18.07	20	13007	9100	63466895
Cholestatic liver injury	29.00	18.07	13	13014	2597	63473398
Joint swelling	28.36	18.07	16	13011	327650	63148345
Forced vital capacity decreased	28.33	18.07	10	13017	1069	63474926
Pain	27.97	18.07	70	12957	740558	62735437
Rheumatoid arthritis	27.35	18.07	9	13018	253810	63222185
Alopecia	27.10	18.07	18	13009	337518	63138477
Coma acidotic	27.00	18.07	6	13021	114	63475881
Haemoglobin decreased	26.86	18.07	78	12949	145407	63330588
Haemorrhagic stroke	26.80	18.07	16	13011	5776	63470219
Drug intolerance	25.41	18.07	16	13011	308645	63167350
Metabolic acidosis	24.98	18.07	38	12989	45031	63430964
Renal failure	24.59	18.07	66	12961	117586	63358409
Ventricular fibrillation	24.56	18.07	20	13007	11847	63464148
Sinusitis	24.48	18.07	8	13019	226645	63249350
Electrocardiogram Q wave abnormal	24.48	18.07	6	13021	177	63475818
Hepatitis cholestatic	24.27	18.07	16	13011	6862	63469133
Rectal haemorrhage	23.94	18.07	39	12988	48991	63427004
Progressive multiple sclerosis	23.80	18.07	9	13018	1169	63474826
Stent malfunction	23.31	18.07	5	13022	80	63475915
Device occlusion	23.23	18.07	16	13011	7371	63468624
Systemic lupus erythematosus	23.23	18.07	7	13020	208911	63267084
Toxicity to various agents	22.98	18.07	11	13016	247239	63228756
Fibroma	22.90	18.07	8	13019	829	63475166
Agranulocytosis	22.87	18.07	27	13000	25107	63450888
Spinal cord haemorrhage	22.77	18.07	6	13021	238	63475757
Hepatitis	22.70	18.07	34	12993	39754	63436241
Blood loss anaemia	22.59	18.07	17	13010	8984	63467011
Sinoatrial block	22.44	18.07	8	13019	880	63475115
Therapeutic product effect decreased	22.35	18.07	6	13021	193181	63282814
Haemoperitoneum	22.27	18.07	11	13016	2730	63473265
Abdominal discomfort	22.09	18.07	20	13007	320865	63155130
Retroperitoneal haemorrhage	22.06	18.07	11	13016	2786	63473209
Stent placement	21.72	18.07	12	13015	3743	63472252
Capillary fragility test	21.53	18.07	4	13023	29	63475966
Drug-induced liver injury	21.01	18.07	33	12994	40189	63435806
Musculoskeletal stiffness	20.86	18.07	6	13021	184612	63291383
Troponin increased	20.83	18.07	17	13010	10104	63465891
Delayed graft function	20.82	18.07	8	13019	1085	63474910
Iron deficiency anaemia	20.79	18.07	23	13004	19946	63456049
Eosinophil cationic protein increased	20.04	18.07	4	13023	44	63475951
Intermittent claudication	19.93	18.07	9	13018	1830	63474165
Cell death	19.84	18.07	10	13017	2591	63473404
Contraindicated product administered	19.74	18.07	10	13017	217638	63258357
Vascular stent occlusion	19.64	18.07	4	13023	49	63475946
Labelled drug-food interaction medication error	19.47	18.07	5	13022	179	63475816
Catheter site haematoma	19.47	18.07	5	13022	179	63475816
Subdural haematoma	19.41	18.07	19	13008	14309	63461686
Swelling	19.15	18.07	17	13010	275361	63200634
Stenosis	18.61	18.07	8	13019	1446	63474549
Bundle branch block right	18.55	18.07	12	13015	4986	63471009
High density lipoprotein decreased	18.51	18.07	9	13018	2161	63473834
Aortic valve calcification	18.07	18.07	6	13021	533	63475462

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vascular stent thrombosis	1503.75	15.94	361	24512	2574	34929484
Thrombosis in device	721.83	15.94	207	24666	3118	34928940
Dyspnoea	460.06	15.94	895	23978	375887	34556171
Acute myocardial infarction	440.94	15.94	339	24534	53380	34878678
Myocardial infarction	333.74	15.94	420	24453	120665	34811393
Chest pain	241.21	15.94	368	24505	126394	34805664
Rhabdomyolysis	232.76	15.94	264	24609	67899	34864159
Angina pectoris	227.02	15.94	184	24689	31179	34900879
Chest discomfort	213.52	15.94	227	24646	54303	34877755
Gastrointestinal haemorrhage	210.85	15.94	286	24587	88191	34843867
Vascular stent stenosis	192.75	15.94	59	24814	1122	34930936
Drug interaction	192.59	15.94	466	24407	225480	34706578
Melaena	178.38	15.94	169	24704	35211	34896847
Sinus arrest	170.28	15.94	59	24814	1681	34930377
Angina unstable	164.98	15.94	103	24770	11550	34920508
Haemorrhage intracranial	158.29	15.94	113	24760	15833	34916225
Cerebral haemorrhage	146.59	15.94	151	24722	34786	34897272
Asphyxia	135.15	15.94	75	24798	6760	34925298
Sinoatrial block	124.97	15.94	35	24838	480	34931578
Coronary artery occlusion	123.56	15.94	84	24789	10878	34921180
Haemorrhage	102.88	15.94	153	24720	51217	34880841
Coronary artery stenosis	99.70	15.94	70	24803	9546	34922512
Acute coronary syndrome	92.74	15.94	77	24796	13468	34918590
Toxicity to various agents	91.89	15.94	16	24857	200346	34731712
Vascular stent occlusion	90.06	15.94	22	24851	169	34931889
Coronary artery thrombosis	88.70	15.94	39	24834	2120	34929938
Bradycardia	87.01	15.94	176	24697	75242	34856816
Rectal haemorrhage	86.55	15.94	124	24749	40125	34891933
Pulmonary haemorrhage	84.24	15.94	65	24808	10239	34921819
Labelled drug-drug interaction medication error	84.22	15.94	76	24797	14863	34917195
Cardiac ventricular thrombosis	75.06	15.94	29	24844	1131	34930927
Febrile neutropenia	74.82	15.94	6	24867	136843	34795215
Coronary artery restenosis	74.65	15.94	28	24845	1006	34931052
Epistaxis	73.28	15.94	141	24732	58110	34873948
Atrioventricular block complete	70.16	15.94	56	24817	9263	34922795
Haematuria	68.96	15.94	126	24747	49940	34882118
Anaemia	68.91	15.94	338	24535	232997	34699061
Cardiac arrest	67.71	15.94	185	24688	95974	34836084
Coronary artery disease	67.08	15.94	122	24751	48183	34883875
Haemorrhagic stroke	66.39	15.94	47	24826	6492	34925566
Intentional product misuse	64.35	15.94	116	24757	45495	34886563
Subarachnoid haemorrhage	57.31	15.94	57	24816	12578	34919480
Pyrexia	56.46	15.94	94	24779	332919	34599139
Subdural haematoma	54.65	15.94	70	24803	20351	34911707
Atrioventricular block	53.46	15.94	45	24828	8018	34924040
Platelet aggregation inhibition	52.95	15.94	10	24863	16	34932042
Shock haemorrhagic	52.94	15.94	52	24821	11302	34920756
Malignant neoplasm progression	50.60	15.94	3	24870	88043	34844015
Electrocardiogram ST segment elevation	49.39	15.94	36	24837	5202	34926856
Rash maculo-papular	48.88	15.94	79	24794	28372	34903686
Brain herniation	48.24	15.94	32	24841	3976	34928082
Device dislocation	48.00	15.94	38	24835	6211	34925847
Gastric haemorrhage	47.85	15.94	47	24826	10214	34921844
Completed suicide	46.83	15.94	7	24866	98161	34833897
Device occlusion	46.45	15.94	38	24835	6507	34925551
White blood cell count decreased	45.08	15.94	7	24866	95438	34836620
Neutropenia	44.99	15.94	28	24845	156750	34775308
Coronary artery dissection	44.38	15.94	14	24859	295	34931763
Upper gastrointestinal haemorrhage	44.03	15.94	71	24802	25447	34906611
Ventricular asystole	43.36	15.94	12	24861	157	34931901
Arterial thrombosis	42.44	15.94	21	24852	1494	34930564
Arterial restenosis	42.26	15.94	10	24863	66	34931992
Pneumonia	42.06	15.94	126	24747	362501	34569557
Diarrhoea	41.38	15.94	141	24732	389771	34542287
Haematoma	41.16	15.94	69	24804	25536	34906522
Drug abuse	41.05	15.94	10	24863	99086	34832972
Disease progression	40.87	15.94	13	24860	108064	34823994
Blood loss anaemia	39.08	15.94	38	24835	8156	34923902
Haematemesis	38.46	15.94	70	24803	27641	34904417
Haemoptysis	38.32	15.94	80	24793	34926	34897132
Thrombosis	37.40	15.94	99	24774	50359	34881699
Gastric ulcer haemorrhage	37.25	15.94	31	24842	5435	34926623
Mixed liver injury	37.17	15.94	24	24849	2849	34929209
Cardiogenic shock	36.64	15.94	67	24806	26551	34905507
Sepsis	36.29	15.94	39	24834	166522	34765536
Sinus bradycardia	35.57	15.94	45	24828	12918	34919140
Haemoglobin decreased	34.84	15.94	174	24699	120598	34811460
Electrocardiogram P wave abnormal	34.81	15.94	10	24863	151	34931907
Overlap syndrome	33.23	15.94	9	24864	108	34931950
Miller Fisher syndrome	32.86	15.94	9	24864	113	34931945
Faeces discoloured	32.19	15.94	46	24827	14832	34917226
Base excess decreased	31.64	15.94	10	24863	212	34931846
Retroperitoneal haematoma	31.31	15.94	21	24852	2657	34929401
Myocardial ischaemia	30.80	15.94	49	24824	17359	34914699
Iron deficiency anaemia	30.17	15.94	37	24836	10292	34921766
Hepatic cytolysis	30.17	15.94	44	24829	14452	34917606
Constipation	29.91	15.94	32	24841	136950	34795108
Device malfunction	29.91	15.94	37	24836	10384	34921674
Lower gastrointestinal haemorrhage	29.47	15.94	35	24838	9417	34922641
Muscle enzyme increased	29.33	15.94	10	24863	271	34931787
Gastric ulcer	29.00	15.94	45	24828	15605	34916453
Cheyne-Stokes respiration	28.92	15.94	10	24863	283	34931775
Troponin increased	28.84	15.94	38	24835	11351	34920707
Pancytopenia	28.68	15.94	16	24857	95141	34836917
Intrapericardial thrombosis	28.40	15.94	7	24866	56	34932002
Myelofibrosis	27.33	15.94	16	24857	1595	34930463
Infusion related reaction	27.18	15.94	3	24870	53054	34879004
Ventricular tachycardia	27.07	15.94	59	24814	26520	34905538
Atrioventricular block second degree	26.89	15.94	22	24851	3766	34928292
Orthopnoea	26.88	15.94	25	24848	5078	34926980
Mallory-Weiss syndrome	26.84	15.94	15	24858	1369	34930689
Heparin-induced thrombocytopenia	26.78	15.94	26	24847	5569	34926489
Left ventricular enlargement	26.65	15.94	12	24861	690	34931368
Diastolic dysfunction	26.24	15.94	27	24846	6200	34925858
Cardiac tamponade	26.20	15.94	25	24848	5241	34926817
Weight increased	26.14	15.94	17	24856	93016	34839042
Oxygen consumption decreased	26.11	15.94	9	24864	252	34931806
Pericardial haemorrhage	25.98	15.94	20	24853	3138	34928920
Neutrophil count decreased	25.90	15.94	3	24870	51101	34880957
Dehydration	25.54	15.94	33	24840	129936	34802122
Suffocation feeling	25.24	15.94	11	24862	585	34931473
Oedema peripheral	25.04	15.94	29	24844	119783	34812275
Ejection fraction decreased	24.84	15.94	47	24826	19107	34912951
Sinus node dysfunction	24.69	15.94	22	24851	4227	34927831
Gout	24.66	15.94	47	24826	19206	34912852
Ventricular fibrillation	24.58	15.94	52	24821	22902	34909156
ECG signs of myocardial ischaemia	24.50	15.94	8	24865	189	34931869
Anterior interosseous syndrome	24.32	15.94	5	24868	15	34932043
Duodenal ulcer	23.92	15.94	33	24840	10299	34921759
Overdose	23.78	15.94	18	24855	91041	34841017
Microcytic anaemia	23.78	15.94	17	24856	2383	34929675
Nasopharyngitis	23.77	15.94	10	24863	69958	34862100
Decreased appetite	23.70	15.94	52	24821	166340	34765718
Product dose omission issue	23.68	15.94	156	24717	119555	34812503
Seizure	23.44	15.94	24	24849	104833	34827225
Circumstance or information capable of leading to medication error	23.36	15.94	15	24858	1764	34930294
Intracardiac thrombus	23.18	15.94	17	24856	2479	34929579
Confusional state	23.15	15.94	42	24831	144118	34787940
Myasthenic syndrome	23.14	15.94	10	24863	521	34931537
Loss of control of legs	23.06	15.94	11	24862	722	34931336
Dizziness	22.98	15.94	247	24626	218274	34713784
Sleep apnoea syndrome	22.89	15.94	47	24826	20274	34911784
Platelet aggregation abnormal	21.83	15.94	5	24868	28	34932030
Reperfusion injury	21.58	15.94	6	24867	80	34931978
Ischaemic stroke	21.49	15.94	43	24830	18207	34913851
Neuropathy peripheral	21.06	15.94	17	24856	83246	34848812
Hepatitis cholestatic	20.88	15.94	27	24846	7920	34924138
Haemorrhagic infarction	20.84	15.94	9	24864	468	34931590
Gastritis erosive	20.22	15.94	23	24850	5909	34926149
Leukopenia	19.77	15.94	10	24863	62846	34869212
Palpitations	19.73	15.94	68	24805	39918	34892140
Stent placement	19.58	15.94	21	24852	5057	34927001
Pulmonary embolism	19.54	15.94	21	24852	89725	34842333
Cardiac failure	19.32	15.94	121	24752	91127	34840931
Pulmonary alveolar haemorrhage	18.92	15.94	25	24848	7487	34924571
Therapy cessation	18.81	15.94	39	24834	16934	34915124
Gingival bleeding	18.73	15.94	24	24849	6976	34925082
Product administration error	18.64	15.94	38	24835	16306	34915752
Pruritus allergic	18.34	15.94	7	24866	264	34931794
Stenosis	18.31	15.94	12	24861	1461	34930597
Electrocardiogram PR prolongation	18.18	15.94	10	24863	885	34931173
Platelet aggregation decreased	18.01	15.94	4	24869	19	34932039
Walking disability	17.89	15.94	10	24863	913	34931145
Hypertrophy	17.88	15.94	8	24865	453	34931605
Apheresis related complication	17.84	15.94	4	24869	20	34932038
Brain natriuretic peptide increased	17.72	15.94	21	24852	5638	34926420
Accelerated idioventricular rhythm	17.55	15.94	6	24867	164	34931894
Foetal exposure during pregnancy	17.52	15.94	3	24870	38098	34893960
Mitral valve incompetence	17.35	15.94	35	24838	14908	34917150
Chronic coronary syndrome	17.18	15.94	6	24867	175	34931883
Infection	16.93	15.94	24	24849	90891	34841167
Hepatocellular injury	16.87	15.94	44	24829	22167	34909891
Mean cell haemoglobin decreased	16.71	15.94	12	24861	1694	34930364
Bladder tamponade	16.65	15.94	8	24865	534	34931524
Urinary bladder haemorrhage	16.44	15.94	12	24861	1737	34930321
Somnolence	16.41	15.94	34	24839	111082	34820976
Calculus urinary	16.37	15.94	11	24862	1396	34930662
Haematochezia	16.30	15.94	71	24802	46463	34885595
Ventricular tachyarrhythmia	16.16	15.94	7	24866	367	34931691
Plasma cell myeloma	15.98	15.94	5	24868	42032	34890026

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vascular stent thrombosis	1679.83	14.54	375	33575	3335	79707103
Rhabdomyolysis	717.16	14.54	481	33469	102650	79607788
Acute myocardial infarction	663.03	14.54	411	33539	76625	79633813
Thrombosis in device	623.75	14.54	184	33766	5258	79705180
Myocardial infarction	550.91	14.54	523	33427	183606	79526832
Dyspnoea	497.03	14.54	1109	32841	855916	78854522
Drug interaction	448.42	14.54	703	33247	414480	79295958
Gastrointestinal haemorrhage	327.05	14.54	357	33593	147362	79563076
Chest pain	299.83	14.54	475	33475	281829	79428609
Angina pectoris	292.89	14.54	213	33737	51519	79658919
Angina unstable	291.98	14.54	142	33808	16385	79694053
Melaena	285.56	14.54	224	33726	60666	79649772
Chest discomfort	253.60	14.54	303	33647	137741	79572697
Cerebral haemorrhage	246.61	14.54	201	33749	57472	79652966
Vascular stent stenosis	239.65	14.54	66	33884	1461	79708977
Asphyxia	226.15	14.54	107	33843	11613	79698825
Haemorrhage intracranial	203.10	14.54	131	33819	26062	79684376
Sinus arrest	202.51	14.54	71	33879	3551	79706887
Coronary artery stenosis	190.15	14.54	97	33853	12387	79698051
Acute coronary syndrome	187.19	14.54	115	33835	21018	79689420
Coronary artery occlusion	185.16	14.54	102	33848	15213	79695225
Sinoatrial block	151.79	14.54	45	33905	1306	79709132
Anaemia	149.49	14.54	472	33478	444543	79265895
Acute kidney injury	141.95	14.54	514	33436	518890	79191548
Haemorrhage	129.23	14.54	176	33774	90942	79619496
Epistaxis	126.87	14.54	194	33756	111321	79599117
Labelled drug-drug interaction medication error	125.84	14.54	100	33850	27550	79682888
Bradycardia	124.52	14.54	214	33736	135343	79575095
Rectal haemorrhage	116.80	14.54	153	33797	76147	79634291
Cardiac arrest	116.07	14.54	238	33712	171858	79538580
Atrioventricular block complete	111.62	14.54	76	33874	16534	79693904
Coronary artery disease	110.79	14.54	138	33812	65336	79645102
Coronary artery thrombosis	104.59	14.54	42	33908	3064	79707374
Toxicity to various agents	103.58	14.54	26	33924	421514	79288924
Cardiogenic shock	100.83	14.54	106	33844	41808	79668630
Coronary artery restenosis	93.69	14.54	31	33919	1298	79709140
Pulmonary haemorrhage	93.37	14.54	65	33885	14652	79695786
Cardiac ventricular thrombosis	88.67	14.54	32	33918	1741	79708697
Electrocardiogram ST segment elevation	88.16	14.54	51	33899	8346	79702092
Upper gastrointestinal haemorrhage	87.89	14.54	98	33852	41282	79669156
Haematuria	85.76	14.54	125	33825	68711	79641727
Subarachnoid haemorrhage	85.52	14.54	76	33874	24389	79686049
Hypersensitivity myocarditis	83.45	14.54	20	33930	248	79710190
Haematoma	80.38	14.54	105	33845	52090	79658348
Haemorrhagic stroke	80.11	14.54	53	33897	10993	79699445
Atrioventricular block	77.55	14.54	57	33893	13984	79696454
Myocardial ischaemia	76.98	14.54	73	33877	25446	79684992
Subdural haematoma	72.94	14.54	78	33872	31356	79679082
Ventricular asystole	71.32	14.54	18	33932	280	79710158
Coronary artery dissection	70.03	14.54	24	33926	1120	79709318
Infusion related reaction	67.65	14.54	9	33941	230228	79480210
Haemoglobin decreased	65.72	14.54	226	33724	221893	79488545
Myopathy	64.28	14.54	60	33890	20503	79689935
Shock haemorrhagic	63.61	14.54	59	33891	20001	79690437
Faeces discoloured	63.60	14.54	70	33880	29057	79681381
Blood loss anaemia	61.98	14.54	52	33898	15446	79694992
Platelet aggregation inhibition	60.63	14.54	14	33936	146	79710292
Vascular stent occlusion	59.70	14.54	15	33935	229	79710209
Febrile neutropenia	59.15	14.54	13	33937	230986	79479452
Ventricular fibrillation	58.37	14.54	70	33880	31856	79678582
Pyrexia	57.94	14.54	127	33823	678582	79031856
Brain herniation	57.03	14.54	37	33913	7426	79703012
Brain natriuretic peptide increased	55.73	14.54	39	33911	8861	79701577
Cardiac failure	54.30	14.54	167	33783	154675	79555763
Haematemesis	53.94	14.54	87	33863	52177	79658261
Alopecia	53.52	14.54	16	33934	231339	79479099
Completed suicide	51.64	14.54	20	33930	245747	79464691
Gastric haemorrhage	51.11	14.54	46	33904	15004	79695434
Haemoptysis	50.82	14.54	88	33862	55911	79654527
Iron deficiency anaemia	49.76	14.54	58	33892	25614	79684824
Sinus bradycardia	48.87	14.54	57	33893	25190	79685248
Duodenal ulcer	47.80	14.54	46	33904	16323	79694115
White blood cell count decreased	47.38	14.54	11	33939	188277	79522161
Retroperitoneal haematoma	47.33	14.54	29	33921	5268	79705170
Gastric ulcer	47.28	14.54	65	33885	33840	79676598
Rash maculo-papular	46.87	14.54	85	33865	55993	79654445
Malignant neoplasm progression	46.06	14.54	3	33947	135987	79574451
Arthropathy	45.26	14.54	10	33940	177101	79533337
Troponin increased	45.06	14.54	48	33902	19207	79691231
Gastric ulcer haemorrhage	43.98	14.54	34	33916	8993	79701445
Pain	42.78	14.54	155	33795	703647	79006791
Sinusitis	42.60	14.54	15	33935	195486	79514952
Hepatitis cholestatic	42.49	14.54	40	33910	13812	79696626
Stomatitis	42.47	14.54	6	33944	146751	79563687
Mixed liver injury	42.38	14.54	31	33919	7547	79702891
Stent placement	41.83	14.54	29	33921	6491	79703947
Arterial thrombosis	41.36	14.54	21	33929	2653	79707785
Cerebral haematoma	41.08	14.54	31	33919	7911	79702527
Nasopharyngitis	41.03	14.54	29	33921	253852	79456586
Cardiac tamponade	41.02	14.54	33	33917	9243	79701195
Lower gastrointestinal haemorrhage	40.96	14.54	42	33908	16083	79694355
Hepatic cytolysis	40.83	14.54	54	33896	27097	79683341
ECG signs of myocardial ischaemia	40.29	14.54	12	33938	354	79710084
Drug reaction with eosinophilia and systemic symptoms	38.78	14.54	85	33865	64159	79646279
Therapeutic product effect decreased	38.49	14.54	11	33939	163852	79546586
Ventricular tachycardia	38.18	14.54	66	33884	41869	79668569
Arthralgia	38.07	14.54	121	33829	571682	79138756
Device malfunction	37.53	14.54	46	33904	21402	79689036
Microcytic anaemia	37.50	14.54	25	33925	5249	79705189
Neutropenia	36.71	14.54	41	33909	287669	79422769
Treatment failure	35.59	14.54	14	33936	170472	79539966
Ischaemic stroke	35.35	14.54	56	33894	33075	79677363
Sinus node dysfunction	35.34	14.54	28	33922	7673	79702765
Diarrhoea	35.34	14.54	225	33725	880264	78830174
Diastolic dysfunction	34.67	14.54	32	33918	10779	79699659
Atrioventricular block second degree	34.45	14.54	27	33923	7285	79703153
Suffocation feeling	34.08	14.54	16	33934	1704	79708734
Eosinophilia	33.25	14.54	65	33885	45280	79665158
Pulmonary alveolar haemorrhage	33.08	14.54	32	33918	11425	79699013
Platelet function test abnormal	33.08	14.54	9	33941	190	79710248
Urinary tract infection	33.01	14.54	41	33909	274471	79435967
Joint swelling	32.77	14.54	45	33905	288601	79421837
Intentional product misuse	32.75	14.54	102	33848	95063	79615375
Intrapericardial thrombosis	31.98	14.54	7	33943	56	79710382
Left ventricular enlargement	31.90	14.54	12	33938	734	79709704
Stenosis	31.68	14.54	17	33933	2405	79708033
Electrocardiogram P wave abnormal	31.51	14.54	10	33940	366	79710072
Toxic skin eruption	31.48	14.54	43	33907	22250	79688188
Pemphigus	31.47	14.54	3	33947	99579	79610859
Constipation	31.26	14.54	45	33905	283005	79427433
Base excess decreased	31.25	14.54	10	33940	376	79710062
Hepatocellular injury	31.06	14.54	65	33885	47528	79662910
Rheumatoid arthritis	30.89	14.54	26	33924	208444	79501994
Diabetic macroangiopathy	30.60	14.54	8	33942	144	79710294
Miller Fisher syndrome	30.23	14.54	9	33941	265	79710173
Muscle enzyme increased	30.21	14.54	10	33940	419	79710019
Mitral valve incompetence	30.08	14.54	48	33902	28517	79681921
Drug abuse	29.86	14.54	16	33934	162675	79547763
Intracardiac thrombus	29.69	14.54	20	33930	4273	79706165
Device dislocation	29.24	14.54	45	33905	25925	79684513
Therapeutic product effect incomplete	28.96	14.54	12	33938	141633	79568805
Pericardial haemorrhage	28.85	14.54	20	33930	4475	79705963
Gingival bleeding	28.63	14.54	35	33915	16241	79694197
Swelling	28.62	14.54	30	33920	216681	79493757
Device occlusion	28.51	14.54	30	33920	11836	79698602
Myelofibrosis	28.43	14.54	16	33934	2484	79707954
Cheyne-Stokes respiration	28.16	14.54	10	33940	519	79709919
Gout	28.03	14.54	43	33907	24706	79685732
Heparin-induced thrombocytopenia	27.88	14.54	27	33923	9655	79700783
Pneumonia	27.86	14.54	166	33784	660080	79050358
Abdominal discomfort	27.55	14.54	40	33910	250687	79459751
Seizure	27.43	14.54	24	33926	188810	79521628
Exposure during pregnancy	27.31	14.54	5	33945	101127	79609311
Drug intolerance	27.23	14.54	44	33906	264075	79446363
Infection	27.11	14.54	38	33912	241674	79468764
Orthopnoea	26.97	14.54	27	33923	10046	79700392
Wound	26.91	14.54	8	33942	116171	79594267
Systemic lupus erythematosus	26.89	14.54	9	33941	121140	79589298
Tachypnoea	26.03	14.54	48	33902	32015	79678423
Oxygen consumption decreased	25.65	14.54	9	33941	451	79709987
Pancytopenia	25.39	14.54	20	33930	165725	79544713
Retroperitoneal haemorrhage	25.34	14.54	20	33930	5450	79704988
Anterior interosseous syndrome	25.21	14.54	5	33945	23	79710415
Syncope	25.03	14.54	146	33804	179303	79531135
Synovitis	24.62	14.54	17	33933	150717	79559721
Neutrophil count decreased	24.62	14.54	5	33945	93954	79616484
Confusional state	24.27	14.54	63	33887	317934	79392504
Muscle necrosis	24.16	14.54	12	33938	1446	79708992
Mobility decreased	23.95	14.54	11	33939	122164	79588274
Cardiac aneurysm	23.71	14.54	12	33938	1506	79708932
Hyperlipidaemia	23.66	14.54	41	33909	26052	79684386
Myasthenic syndrome	23.65	14.54	10	33940	832	79709606
Intermittent claudication	23.59	14.54	16	33934	3455	79706983
Acid base balance abnormal	23.54	14.54	8	33942	364	79710074
Peripheral swelling	23.30	14.54	50	33900	269567	79440871
Intraventricular haemorrhage	22.92	14.54	18	33932	4869	79705569
Oropharyngeal pain	22.79	14.54	9	33941	109344	79601094
Ventricular tachyarrhythmia	22.78	14.54	8	33942	402	79710036
Weight increased	22.69	14.54	53	33897	277333	79433105
Myositis	22.69	14.54	34	33916	19134	79691304
Somnolence	22.64	14.54	42	33908	238939	79471499
Herpes zoster	22.32	14.54	6	33944	93077	79617361
Ejection fraction decreased	22.30	14.54	47	33903	34530	79675908
Coma acidotic	21.95	14.54	6	33944	129	79710309
Thrombosis	21.79	14.54	82	33868	84018	79626420
Neuropathy peripheral	21.70	14.54	17	33933	141288	79569150
Disease progression	21.67	14.54	28	33922	184334	79526104
Cardiac failure acute	21.59	14.54	33	33917	18896	79691542
Ischaemic cardiomyopathy	21.30	14.54	21	33929	7674	79702764
Electrocardiogram RR interval prolonged	21.27	14.54	4	33946	13	79710425
Vascular pseudoaneurysm	21.09	14.54	15	33935	3495	79706943
Oedema peripheral	20.80	14.54	48	33902	252240	79458198
Dizziness	20.43	14.54	326	33624	526115	79184323
Gastritis erosive	20.18	14.54	24	33926	10823	79699615
Arterial restenosis	20.17	14.54	5	33945	72	79710366
Arthritis	20.07	14.54	12	33938	114868	79595570
Apheresis related complication	19.89	14.54	4	33946	20	79710418
Abnormal loss of weight	19.81	14.54	21	33929	8355	79702083
Reperfusion injury	19.59	14.54	6	33944	195	79710243
Cardiac discomfort	19.58	14.54	10	33940	1278	79709160
Fatigue	19.44	14.54	279	33671	929448	78780990
Forced vital capacity decreased	19.40	14.54	11	33939	1732	79708706
Cerebellar haematoma	19.36	14.54	8	33942	628	79709810
Subcutaneous haematoma	19.35	14.54	13	33937	2764	79707674
Hypertensive crisis	19.31	14.54	33	33917	20737	79689701
Haematochezia	19.12	14.54	81	33869	87564	79622874
Mallory-Weiss syndrome	19.04	14.54	13	33937	2839	79707599
Immune-mediated myositis	18.97	14.54	14	33936	3453	79706985
Duodenal ulcer haemorrhage	18.81	14.54	19	33931	7144	79703294
Overlap syndrome	18.68	14.54	9	33941	1015	79709423
Dyspnoea exertional	18.64	14.54	80	33870	86993	79623445
Capillary fragility test	18.62	14.54	4	33946	29	79710409
Injury	18.57	14.54	5	33945	77491	79632947
Migraine	18.56	14.54	7	33943	87486	79622952
Gastrointestinal angiodysplasia	18.32	14.54	9	33941	1060	79709378
Haemoperitoneum	18.25	14.54	15	33935	4328	79706110
Injection site pain	18.25	14.54	17	33933	129821	79580617
Myocardial rupture	18.18	14.54	6	33944	249	79710189
Loss of control of legs	18.18	14.54	11	33939	1954	79708484
Pericarditis	18.05	14.54	11	33939	104225	79606213
Deep vein thrombosis	18.00	14.54	15	33935	120904	79589534
Bundle branch block right	17.88	14.54	23	33927	11228	79699210
Haemorrhagic infarction	17.85	14.54	8	33942	766	79709672
Fibromyalgia	17.77	14.54	3	33947	64337	79646101
Alveolar proteinosis	17.70	14.54	8	33942	781	79709657
Myocardial necrosis marker increased	17.52	14.54	13	33937	3233	79707205
Hypertrophy	17.50	14.54	8	33942	802	79709636
Headache	17.49	14.54	186	33764	653586	79056852
Contraindicated product administered	17.42	14.54	25	33925	157513	79552925
Progressive multiple sclerosis	17.21	14.54	9	33941	1208	79709230
Eosinophil cationic protein increased	17.13	14.54	4	33946	44	79710394
Coronary revascularisation	17.05	14.54	4	33946	45	79710393
Injection site erythema	17.02	14.54	6	33944	78191	79632247
Impaired healing	17.01	14.54	8	33942	87647	79622791
Fibroma	16.74	14.54	8	33942	887	79709551
Spinal cord haemorrhage	16.73	14.54	7	33943	567	79709871
Eyelid haematoma	16.44	14.54	4	33946	53	79710385
Musculoskeletal stiffness	16.35	14.54	31	33919	174977	79535461
Lipid metabolism disorder	16.34	14.54	6	33944	343	79710095
Coronary artery reocclusion	16.28	14.54	5	33945	164	79710274
Ill-defined disorder	16.26	14.54	4	33946	65871	79644567
Procalcitonin increased	16.14	14.54	12	33938	2994	79707444
Splenic rupture	16.04	14.54	11	33939	2418	79708020
Overdose	16.04	14.54	34	33916	184172	79526266
Subdural haemorrhage	16.03	14.54	16	33934	5932	79704506
Haemorrhoidal haemorrhage	16.00	14.54	17	33933	6778	79703660
Calculus urinary	15.92	14.54	11	33939	2449	79707989
Back pain	15.88	14.54	71	33879	304109	79406329
Lower respiratory tract infection	15.83	14.54	19	33931	129201	79581237
Arteriosclerosis	15.70	14.54	28	33922	18199	79692239
Catheter site haematoma	15.69	14.54	6	33944	384	79710054
Pulmonary embolism	15.52	14.54	31	33919	171623	79538815
Subcapsular hepatic haematoma	15.46	14.54	3	33947	12	79710426
Percutaneous coronary intervention	15.41	14.54	6	33944	403	79710035
Hypersensitivity	15.06	14.54	59	33891	262180	79448258
Electrocardiogram PR prolongation	15.00	14.54	9	33941	1574	79708864
Cardiac failure chronic	15	14.54	21	33929	11114	79699324
Hepatitis	14.98	14.54	55	33895	55672	79654766
Intentional overdose	14.74	14.54	14	33936	105946	79604492
Accelerated idioventricular rhythm	14.62	14.54	5	33945	232	79710206

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AC24	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
FDA PE	N0000008832	Decreased Platelet Aggregation
MeSH PA	D006401	Hematologic Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D010975	Platelet Aggregation Inhibitors
MeSH PA	D058914	Purinergic Antagonists
MeSH PA	D058919	Purinergic P2 Receptor Antagonists
MeSH PA	D058921	Purinergic P2Y Receptor Antagonists
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA EPC	N0000182142	P2Y12 Platelet Inhibitor
FDA MoA	N0000182143	P2Y12 Receptor Antagonists
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190115	Cytochrome P450 3A5 Inhibitors
FDA MoA	N0000190482	Phenylalanine Hydroxylase Activators
CHEBI has role	CHEBI:50427	platelet aggregation inhibitors
CHEBI has role	CHEBI:68563	ADP receptor subtype P2Y12 antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute coronary syndrome	indication	394659003
Peripheral vascular disease	indication	400047006
Percutaneous coronary intervention	indication	415070008
Myocardial Reinfarction Prevention	indication
Intracranial hemorrhage	contraindication	1386000
Hepatic failure	contraindication	59927004
Disease of liver	contraindication	235856003	DOID:409
Surgical procedure	contraindication	387713003
Significant Bleeding	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.07	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	RE46276	Oct. 30, 2024	TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	10300065	Jan. 27, 2036	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	10300065	Jan. 27, 2036	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	10300065	Jan. 27, 2036	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	10300065	Jan. 27, 2036	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	May 28, 2023	TO REDUCE THE RISK OF A FIRST MYOCARDIAL INFARCTION (MI) OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) AT HIGH RISK FOR SUCH EVENTS
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	May 28, 2023	TO REDUCE THE RISK OF A FIRST MYOCARDIAL INFARCTION (MI) OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) AT HIGH RISK FOR SUCH EVENTS
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	Nov. 5, 2023	REDUCE THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (NIH STROKE SCALE SCORE <=5) OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK (TIA)
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	Nov. 5, 2023	REDUCE THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (NIH STROKE SCALE SCORE <=5) OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK (TIA)
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	Nov. 28, 2023	PEDIATRIC EXCLUSIVITY
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	Nov. 28, 2023	PEDIATRIC EXCLUSIVITY
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	May 5, 2024	PEDIATRIC EXCLUSIVITY
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	May 5, 2024	PEDIATRIC EXCLUSIVITY
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	May 9, 2025	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY HESTIA3
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	May 9, 2025	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY HESTIA3
60MG	BRILINTA	ASTRAZENECA	N022433	Sept. 3, 2015	RX	TABLET	ORAL	Nov. 9, 2025	PEDIATRIC EXCLUSIVITY
90MG	BRILINTA	ASTRAZENECA	N022433	July 20, 2011	RX	TABLET	ORAL	Nov. 9, 2025	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
P2Y purinoceptor 12	GPCR	Q9H244	P2Y12_HUMAN	NEGATIVE ALLOSTERIC MODULATOR	Ki	7.85		CHEMBL	CHEMBL
Equilibrative nucleoside transporter 1	Transporter	Q99808	S29A1_HUMAN	INHIBITOR	Ki	7.30		IUPHAR
P2Y purinoceptor 12	GPCR		P2Y12_RAT		IC50	5.38		CHEMBL

External reference:

ID	Source
4030908	VUID
N0000182973	NUI
D09017	KEGG_DRUG
4030908	VANDF
C1999375	UMLSCUI
CHEBI:68558	CHEBI
TIQ	PDB_CHEM_ID
CHEMBL398435	ChEMBL_ID
D000077486	MESH_DESCRIPTOR_UI
DB08816	DRUGBANK_ID
1765	IUPHAR_LIGAND_ID
8772	INN_ID
GLH0314RVC	UNII
9871419	PUBCHEM_CID
1116632	RXNORM
182026	MMSL
235692	MMSL
27677	MMSL
d07721	MMSL
013611	NDDF
698805004	SNOMEDCT_US
704464003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BRILINTA	HUMAN PRESCRIPTION DRUG LABEL	1	0186-0776	TABLET	60 mg	ORAL	NDA	31 sections
BRILINTA	HUMAN PRESCRIPTION DRUG LABEL	1	0186-0776	TABLET	60 mg	ORAL	NDA	31 sections
BRILINTA	HUMAN PRESCRIPTION DRUG LABEL	1	0186-0777	TABLET	90 mg	ORAL	NDA	31 sections
BRILINTA	HUMAN PRESCRIPTION DRUG LABEL	1	0186-0777	TABLET	90 mg	ORAL	NDA	31 sections
BRILINTA	HUMAN PRESCRIPTION DRUG LABEL	1	55154-9618	TABLET	90 mg	ORAL	NDA	31 sections
BRILINTA	HUMAN PRESCRIPTION DRUG LABEL	1	55154-9618	TABLET	90 mg	ORAL	NDA	31 sections
BRILINTA	HUMAN PRESCRIPTION DRUG LABEL	1	55154-9618	TABLET	90 mg	ORAL	NDA	31 sections
ticagrelor	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1134	TABLET	90 mg	ORAL	ANDA	28 sections
ticagrelor	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1134	TABLET	90 mg	ORAL	ANDA	28 sections